These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 19300249)

  • 61. HIV encephalitis in a patient on antiretroviral therapy: a case report.
    Hlebowicz M; Parczewski M; Jakubowski P
    Int J STD AIDS; 2019 May; 30(6):617-619. PubMed ID: 30722753
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Updated research nosology for HIV-associated neurocognitive disorders.
    Antinori A; Arendt G; Becker JT; Brew BJ; Byrd DA; Cherner M; Clifford DB; Cinque P; Epstein LG; Goodkin K; Gisslen M; Grant I; Heaton RK; Joseph J; Marder K; Marra CM; McArthur JC; Nunn M; Price RW; Pulliam L; Robertson KR; Sacktor N; Valcour V; Wojna VE
    Neurology; 2007 Oct; 69(18):1789-99. PubMed ID: 17914061
    [TBL] [Abstract][Full Text] [Related]  

  • 63. AIDS dementia.
    Clifford DB
    Med Clin North Am; 2002 May; 86(3):537-50, vi. PubMed ID: 12168558
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex.
    Brew BJ
    AIDS; 2004 Jan; 18 Suppl 1():S75-8. PubMed ID: 15075501
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Sequence heterogeneity and viral dynamics in cerebrospinal fluid and plasma during antiretroviral therapy.
    Haas DW
    J Neurovirol; 2004; 10 Suppl 1():33-7. PubMed ID: 14982737
    [TBL] [Abstract][Full Text] [Related]  

  • 66. CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy.
    Valle M; Price RW; Nilsson A; Heyes M; Verotta D
    Brain; 2004 May; 127(Pt 5):1047-60. PubMed ID: 15013955
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Response to "Persistence of Neuropsychologic Deficits Despite Long-Term Highly Active Antiretroviral Therapy in Patients With HIV-Related Neurocognitive Impairment".
    Garvey L; Thomson EC; Main J; Winston A
    J Acquir Immune Defic Syndr; 2007 Dec; 46(5):656-7, author reply 657-8. PubMed ID: 18043322
    [No Abstract]   [Full Text] [Related]  

  • 68. Biomarkers, laboratory, and animal models for the design and development of adjunctive therapies for HIV-1 dementia and other neuroinflammatory disorders.
    Gendelman HE
    J Neuroimmune Pharmacol; 2007 Mar; 2(1):8-13. PubMed ID: 18040820
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Neurocognitive impairment and neuroCART.
    Wright E
    Curr Opin HIV AIDS; 2011 Jul; 6(4):303-8. PubMed ID: 21546833
    [TBL] [Abstract][Full Text] [Related]  

  • 70. When do models of NeuroAIDS faithfully imitate "the real thing"?
    Gelman BB; Endsley J; Kolson D
    J Neurovirol; 2018 Apr; 24(2):146-155. PubMed ID: 29256039
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [HIV glycoprotein 120: possible etiological agent of AIDS-associated dementia].
    Galicia O; Sánchez-Alavez M; Méndez Díaz M; Navarro L; Prospero-García O
    Rev Invest Clin; 2002; 54(5):437-52. PubMed ID: 12587419
    [TBL] [Abstract][Full Text] [Related]  

  • 72. HAART & the molecular biology of AIDS dementia complex.
    Saksena NK; Smit TK
    Indian J Med Res; 2005 Apr; 121(4):256-69. PubMed ID: 15817943
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Biotypes of HIV-associated neurocognitive disorders based on viral and immune pathogenesis.
    Johnson TP; Nath A
    Curr Opin Infect Dis; 2022 Jun; 35(3):223-230. PubMed ID: 35665716
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effects of antiretroviral therapy on cognitive impairment.
    Liner KJ; Hall CD; Robertson KR
    Curr HIV/AIDS Rep; 2008 May; 5(2):64-71. PubMed ID: 18510891
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Nef exosomes isolated from the plasma of individuals with HIV-associated dementia (HAD) can induce Aβ(1-42) secretion in SH-SY5Y neural cells.
    Khan MB; Lang MJ; Huang MB; Raymond A; Bond VC; Shiramizu B; Powell MD
    J Neurovirol; 2016 Apr; 22(2):179-90. PubMed ID: 26407718
    [TBL] [Abstract][Full Text] [Related]  

  • 77. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy.
    Neuenburg JK; Brodt HR; Herndier BG; Bickel M; Bacchetti P; Price RW; Grant RM; Schlote W
    J Acquir Immune Defic Syndr; 2002 Oct; 31(2):171-7. PubMed ID: 12394795
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Changing patterns in the neuropathogenesis of HIV during the HAART era.
    Langford TD; Letendre SL; Larrea GJ; Masliah E
    Brain Pathol; 2003 Apr; 13(2):195-210. PubMed ID: 12744473
    [TBL] [Abstract][Full Text] [Related]  

  • 79. HIV-associated neurocognitive disorders: a historical review.
    Rosca EC; Rosca O; Simu M; Chirileanu RD
    Neurologist; 2012 Mar; 18(2):64-7. PubMed ID: 22367830
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Normalisation of cerebrospinal fluid biomarkers parallels improvement of neurological symptoms following HAART in HIV dementia--case report.
    Andersson LM; Hagberg L; Rosengren L; Fuchs D; Blennow K; Gisslén M
    BMC Infect Dis; 2006 Sep; 6():141. PubMed ID: 16978408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.